You are here

Press Release Archive

 
- Pfizer Declares First-Quarter 2018 Dividend

The board of directors of Pfizer Inc. today declared a 34-cent first-quarter 2018 dividend on the company’s common stock, payable March 1, 2018, to shareholders of record at the close of business on February 2, 2018. Pfizer increased the dividend by approximately 6 percent, to 34 cents from 32 cents per share. The first-quarter 2018 cash dividend will be the 317th consecutive quarterly dividend paid by Pfizer.

 
- Pfizer Inc. Announces Expiration and Results of its Private Exchange Offer for its 6.500 per cent. Notes due 2038 and Related Tender Offer

Pfizer today announced the expiration and results of its previously announced offers to exchange and to repurchase any and all of its outstanding £1,500,000,000 6.500 per cent. Notes due 2038 (the “Old Notes”).

 
- Pfizer Announces FDA Approval of XELJANZ® (tofacitinib) and XELJANZ® XR for the Treatment of Active Psoriatic Arthritis

Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has approved XELJANZ® 5 mg twice daily (BID) and XELJANZ® XR (tofacitinib) extended release 11 mg once daily (QD) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). XELJANZ/XELJANZ XR is the first and only Janus kinase (JAK) inhibitor approved by the FDA for both moderate to severe rheumatoid arthritis (RA) and active PsA.

 
- Pfizer Inc. Announces Pricing Terms of Private Exchange Offer for its 6.500 per cent. Notes due 2038 Open to Certain Investors and Related Tender Offer Open to All Investors

Pfizer Inc. (NYSE: PFE) (“Pfizer”) today announced the pricing terms of its previously announced offers to exchange and to repurchase any and all of its outstanding £1,500,000,000 6.500 per cent. Notes due 2038 (the “Old Notes”).

 
- Pfizer Initiates Phase 3 Program for PF-04965842, a JAK1 Inhibitor in Development for Moderate-to-Severe Atopic Dermatitis

Pfizer Inc. (NYSE:PFE) today announced the initiation of a Phase 3 program for its once-daily Janus kinase 1 (JAK1) inhibitor PF-04965842, to evaluate the efficacy and safety of PF-04965842 for the treatment of moderate-to-severe atopic dermatitis (AD).

 
- FDA Approves New Pfizer Biosimilar

Pfizer Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI™ (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab)  for all eligible indications of the reference product.

 
- Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Data Published in New England Journal of Medicine Demonstrate the Vaccine’s Immunogenicity

Pfizer Inc. (NYSE: PFE) today announced that detailed results from two pivotal Phase 3 studies of TRUMENBA® (Meningococcal Group B Vaccine) were published in the New England Journal of Medicine (NEJM). Data from both studies demonstrated that TRUMENBA, as a three-dose series, elicits a protective immune response against diverse meningococcal group B (MenB) strains representative of prevalent strains causing invasive disease in the United States and Europe.

 
- U.S. Food And Drug Administration Extends Action Date For XELJANZ® (Tofacitinib) Supplemental New Drug Application In Ulcerative Colitis By Three Months

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib), an oral treatment under investigation for adult patients with moderately to severely active ulcerative colitis (UC).

 
- Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition

Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc., today announced that, with a cumulative follow-up of more than 13 patient years of observation, all 11 participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for the treatment of patients with hemophilia B had discontinued routine infusions of factor IX concentrates and shown sustained steady-state factor IX activity levels with no serious adverse events, thrombotic events or factor IX inhibitors observed.

 
- Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer

Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 EMBRACA trial in patients with germline (inherited) BRCA1/2-positive (gBRCA+) locally advanced and/or metastatic breast cancer (MBC) demonstrated superior progression-free survival (PFS) in patients treated with talazoparib, compared to patients who received physician’s choice standard of care chemotherapy. Median PFS was 8.6 months (95% CI: 7.2, 9.3) for patients treated with talazoparib and 5.6 months (95% CI: 4.2, 6.7) for those treated with chemotherapy [HR: 0.54 (95% CI: 0.41, 0.71), p<0.0001].

 
- Pfizer Inc. Announces (i) Private Exchange Offer for its 6.500 per cent. Notes due 2038 Open to Certain Investors and Related Tender Offer Open to All Investors and (ii) Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents

Pfizer Inc. (NYSE:PFE) (“Pfizer”) today announced that it has commenced a private offer to exchange (the “Exchange Offer”) any and all of its outstanding £1,500,000,000 6.500 per cent. Notes due 2038 (the “Old Notes”) in exchange for newly issued debt securities of Pfizer (the “New Notes”), on the terms and subject to the conditions set forth in the Offering Memorandum dated December 7, 2017 (the “Offering Memorandum” and, together with the accompanying exchange offer notice of guaranteed delivery, the “Exchange Offer Documents”).

 
- Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. (NYSE:PFE), today announced that The New England Journal of Medicine has published interim data as of July 25, 2017, from the Phase 1/2 clinical trial of SPK-9001, an investigational gene therapy for hemophilia B. 

 
- Updated Data from Phase 3 Trial of IBRANCE® (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival

Pfizer Inc. (NYSE:PFE) today announced updated progression-free survival (PFS) results from the Phase 3 PALOMA-2 trial reinforcing the clinical benefit of IBRANCE® (palbociclib) combined with letrozole. 

 
- Bristol-Myers Squibb and Pfizer Alliance Urge People to ‘Tune in to AFib, Take Note of Stroke Risk’

The Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia today launched ‘Tune in to AFib, Take Note of Stroke Risk’ to educate the estimated nearly seven million Americans in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their increased risk of stroke. People with AFib are five times more likely to have a stroke than those who do not have the condition, and these strokes are more severe and more likely to be fatal than strokes not associated with AFib.

 
- Pfizer Unveils 2017 ASPIRE Oncology/Hematology Clinical Research Awards Winners; Grants Totaling More than $6M in 2017

Pfizer Inc. (NYSE:PFE) today announced the recipients of the expanded Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Oncology/Hematology Clinical Research Awards. Nine grants totaling more than $6 million (USD) in funding were awarded to investigators in the United States (U.S.) to support clinical research projects involving Pfizer medicines in both breast and hematologic cancers for 2017. This program started in 2015 in breast cancer and chronic myeloid leukemia.

 
- Pfizer Enters into Agreement to Develop and Commercialize CRESEMBA® (isavuconazole) in China and Asia Pacific Region

Pfizer and Basilea Pharmaceutica Ltd., an international biopharmaceutical company specializing in the research and development of anti-infective and oncological medicines, today announced they have entered into an agreement whereby Pfizer will be granted the exclusive development and commercialization rights in China and several countries in the Asia Pacific region to CRESEMBA (isavuconazole). CRESEMBA is a novel antifungal medicine for the treatment of adult patients with diagnosed invasive aspergillosis and mucormycosis1, two serious infections associated with significant morbidity and mortality among immunocompromised patients, such as those with advanced HIV and those with cancer.

 
- Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Gastric 300 trial did not meet its primary endpoint of superior overall survival (OS) with single-agent avelumab* . . .

 
- Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® . . . 

 
- Pfizer Names Albert Bourla Chief Operating Officer

Pfizer today announced that Albert Bourla has been named Chief Operating Officer effective January 1, 2018. 

 
- BMS-Pfizer Alliance To Unveil Real-World Data Analyses - Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation

Bristol-Myers Squibb Company and Pfizer Inc. plan to release real-world data analyses of outcomes associated with direct oral anticoagulants...

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.